Results 41 to 50 of about 15,728 (206)

WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME

Рациональная фармакотерапия в кардиологии, 2018
The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS).
M. Yu. Gilyarov, Е. V. Konstantinova
doaj   +1 more source

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms [PDF]

Neurointervention, 2018
Thromboembolism is one of the major complications of stent assisted coiling in treatment of cerebral aneurysm. Clopidogrel resistance is so common and prasugrel is more effective in its rapid and potent effect.
Dongwhane Lee, Yunsun Song, Minkyu Han, Danbi Park, Dae Chul Suh   +4 more
doaj   +1 more source

Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.

JAMA cardiology, 2021
Importance It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI).
J. Coughlan, A. Aytekin, S. Lahu, G. Ndrepepa, M. Menichelli, K. Mayer, J. Wöhrle, I. Bernlochner, S. Gewalt, B. Witzenbichler, W. Hochholzer, D. Sibbing, S. Cassese, D. Angiolillo, R. Hemetsberger, C. Valina, Arne M. Müller, S. Kufner, C. Liebetrau, E. Xhepa, A. Hapfelmeier, H. Sager, M. Joner, M. Fusaro, G. Richardt, K. Laugwitz, F. Neumann, H. Schunkert, Stefanie Schüpke, A. Kastrati   +29 more
semanticscholar   +1 more source

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Management of patients with non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS) is based on 2020 European Society of Cardiology guidelines, which recommend the preferential use of prasugrel over ticagrelor. Because the selection of the
Mustafa Yildirim, Matthias Mueller‐Hennessen, Barbara Ruth Milles, Moritz Biener, Hauke Hund, Norbert Frey, Evangelos Giannitsis, Christian Salbach   +7 more
doaj   +1 more source

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor

Journal of Thrombosis and Thrombolysis, 2021
Prasugrel and ticagrelor are potent oral platelet P2Y12 inhibitors and are recommended over clopidogrel in patients with acute coronary syndrome (ACS).
D. Angiolillo, L. Been, M. Rubinstein, Michael Martin, F. Rollini, Francesco Franchi   +5 more
semanticscholar   +1 more source

Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST‐Elevation Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundEarly withdrawal of recommended antiplatelet treatment with clopidogrel adversely affects prognosis following percutaneous coronary interventions. Optimal antiplatelet treatment is essential following ST‐segment elevation myocardial infarction (
Konstantinos C. Koskinas, Thomas Zanchin, Roland Klingenberg, Baris Gencer, Fabrice Temperli, Andreas Baumbach, Marco Roffi, Aris Moschovitis, Oliver Muller, David Tüller, Stefan Stortecky, Francois Mach, Thomas F. Lüscher, Christian M. Matter, Thomas Pilgrim, Dik Heg, Stephan Windecker, Lorenz Räber   +17 more
doaj   +1 more source

Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial

Journal of Clinical Medicine, 2021
East Asians treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) generally experience more intense platelet inhibitory responses resulting in an increased risk of major bleeding.
C. Jin, Moo-Hyun Kim, Kai Song, Xuan Jin, K. Lee, Jong-Sung Park, Young-Rak Cho, S. Yun, Michael S. Lee   +8 more
semanticscholar   +1 more source

Simultaneous Determination of Prasugrel and Aspirin by Second Order and Ratio First Order Derivative Ultraviolet Spectrophotometry

Journal of Spectroscopy, 2013
Two simple, accurate, and precise UV derivative spectrophotometric methods for the simultaneous determination of Prasugrel and Aspirin in synthetic mixture form have been developed. The first method involves measurement of second order derivative spectra
Shahabuddin N. Alvi, Mehul N. Patel, Prakash B. Kathiriya, Bhavna A. Patel, Shraddha J. Parmar   +4 more
doaj   +1 more source

Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.

Journal of the American College of Cardiology, 2020
BACKGROUND Current guidelines recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) myocardial infarction (MI).
C. Valina, F. Neumann, M. Menichelli, K. Mayer, J. Wöhrle, I. Bernlochner, A. Aytekin, G. Richardt, B. Witzenbichler, D. Sibbing, S. Cassese, D. Angiolillo, S. Kufner, C. Liebetrau, C. Hamm, E. Xhepa, A. Hapfelmeier, H. Sager, I. Wustrow, M. Joner, D. Trenk, K. Laugwitz, H. Schunkert, Stefanie Schüpke, A. Kastrati   +24 more
semanticscholar   +1 more source

Eversion endarterectomy under full prasugrel treatment

SAGE Open Medical Case Reports, 2017
The third-generation thienopyridine prasugrel has much stronger antiplatelet effect compared to other current antiplatelet inhibitors and exhibits practically zero resistance in healthy people.
Thomas Kotsis, Panagitsa Christoforou, Nikolaos Asaloumidis, Erifyli Argyra   +3 more
doaj   +1 more source